Upfront investment to develop lion's mane mushroom products in Bangladesh
First written in FY2017-Q2. 2 of 4 entries say "Restated". Latest entry: FY2018-Q1.
No other company in this theme has enough history to compare yet.
- FY2018-Q1RestatedAnnual report
「There are no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
There have been no material changes in the risk disclosures concerning upfront investment to develop lion's mane mushroom products in Bangladesh. - FY2017RestatedAnnual report
「Upfront investment, including joint research and research and development expenses to develop lion's mane mushroom products in the People's Republic of Bangladesh, increased from the previous fiscal year.」
The company continues its research and development and upfront investment to develop lion's mane mushroom products in Bangladesh, and the investment amount increased from the previous fiscal year. - FY2017-Q3Increase in upfront investmentAnnual report
「Upfront investment, including research and development expenses, to develop lion's mane mushroom products in the People's Republic of Bangladesh increased from the same period of the previous year.」
The company continues its research and development and upfront investment to develop lion's mane mushroom products in Bangladesh, but the investment amount increased from the same period of the previous year. - FY2017-Q2First statedAnnual report
「The company made upfront investments to develop lion's mane mushroom products in the People's Republic of Bangladesh.」
The company stated for the first time that it had made upfront investments to develop lion's mane mushroom products in the People's Republic of Bangladesh.